Systems biology and the discovery of diagnostic biomarkers

Disease Markers

Volumn 28, Issue 4, 2010, Pages 199-207

  Wang, Kai ^a   Lee, Inyoul ^a   Carlson, George ^b   Hood, Leroy ^a   Galas, David ^a  

^a INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^b MCLAUGHLIN RESEARCH INSTITUTE   (United States)

Author keywords

biomarkers; drug induced liver injury; microRNA; organ specific proteins; prion disease; Systems biology; systems medicine

Indexed keywords

BIOLOGICAL MARKER;

BIOLOGY; BLOOD; CLINICAL MEDICINE; COMPREHENSION; DIAGNOSTIC PROCEDURE; DYNAMICS; HUMAN; IN VITRO STUDY; INFORMATION; KNOWLEDGE; LIVER INJURY; LIVER TOXICITY; MODEL; NONHUMAN; PATHOLOGY; PRION DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 77954127988     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.3233/DMA-2010-0697     Document Type: Review

References (60)

1. L. Hood et al., Systems biology and new technologies enable predictive and preventative medicine, Science 306(5696) (2004), 640-643.
2. R. Mazzucchelli et al., Prostate tissue and serum markers, Adv Clin Path 4(3) (2000), 111-120.
3. W.W. Hochreiter, The issue of prostate cancer evaluation in men with elevated prostate-specific antigen and chronic prostatitis, Andrologia 40(2) (2008), 130-133.
4. X. Wang et al., Autoantibody signatures in prostate cancer, N Engl J Med 353(12) (2005), 1224-1235.
5. E. Papadopoulou et al., Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer, Ann N Y Acad Sci 1075 (2006), 235-243.
6. K.D. Sorensen and T.F. Orntoft, Discovery of prostate cancer biomarkers by microarray gene expression profiling, Expert Rev Mol Diagn 10(1), 49-64.
7. C.R. Scherzer et al., Molecular markers of early Parkinson's disease based on gene expression in blood, Proc Natl Acad Sci U S A, 2007.
8. K.S. Solanky et al., Application of biofluid 1H nuclear magnetic resonance-based metabonomic techniques for the analysis of the biochemical effects of dietary isoflavones on human plasma profile, Anal Biochem 323(2) (2003), 197-204.
9. A. Deguchi et al., Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G, Mol Cancer Ther 1(10) (2002), 803-809.
10. P.A. Norton et al., N-linked glycosylation of the liver cancer biomarker GP73, J Cell Biochem 104(1) (2008), 136-149.
11. P.M. Drake et al., Sweetening the Pot: Adding Glycosylation to the Biomarker Discovery Equation, Clin Chem, 2009.
12. S.B. Prusiner, Prions, Proc Natl Acad Sci U S A 95(23) (1998), 13363-13383.
13. S.B. Prusiner, Prion diseases and the BSE crisis, Science 278(5336) (1997), 245-251.
14. S.B. Prusiner, An introduction to Prion Biology andDisease, in Prion Biology and Diseases. Cold Spring Harbor Laboratory Press, 2003, pp. 1-88.
15. S.J. DeArmond and S.B. Prusiner, Etiology and pathogenesis of prion diseases, Am J Pathol 146(4) (1995), 785-811.
16. D. Westaway and G.A. Carlson, Mammalian prion proteins: enigma, variation and vaccination, Trends Biochem Sci 27(6) (2002), 301-307.
17. S.J. DeArmond et al., Three scrapie prion isolates exhibit different accumulation patterns of the prion protein scrapie isoform, Proc Natl Acad Sci U S A 90(14) (1993), 6449-6453.
18. M. Bruce et al., Transmission of bovine spongiform encephalopathy and scrapie to mice: strain variation and the species barrier, Philosophical Transactions 343 (1994), 405-411.
19. D. Hwang et al., A systems approach to prion disease, Mol Syst Biol 5 (2009), 252.
20. A.F.Keller,M. Gravel and J. Kriz, Live imaging of amyotrophic lateral sclerosis pathogenesis: disease onset is characterized by marked induction of GFAP in Schwann cells, Glia 57(10) (2009), 1130-1142.
21. M.E. Phelps, Inaugural article: positron emission tomography provides molecular imaging of biological processes, Proc Natl Acad Sci U S A 97(16) (2000), 9226-9233.
22. B. Boland et al., Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease, J Neurosci 28(27) (2008), 6926-6937.
23. A.M. Cataldo et al., Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects, Am J Pathol 173(2) (2008), 370-384.
24. L. Meda, P. Baron and G. Scarlato, Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins, Neurobiol Aging 22(6) (2001), 885-893.
25. R.E. Mrak and W.S. Griffin, Potential inflammatory biomarkers in Alzheimer's disease, J Alzheimers Dis 8(4) (2005), 369-375.
26. C.M. Norris et al., Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models, J Neurosci 25(18) (2005), 4649-4658.
27. P.H. Reddy et al., Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease, Hum Mol Genet 13(12) (2004), 1225-1240.
28. M.V. Kolev et al., Implication of complement system and its regulators in Alzheimer's disease, Curr Neuropharmacol 7(1) (2009), 1-8.
29. F.S. Shie et al., Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferatoractivated receptor gamma, Curr Med Chem 16(6) (2009), 643-651.
30. S.C. Tang et al., Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal, Exp Neurol 213(1) (2008), 114-121.
31. J.K. Yao et al., Reduced membrane lipids in the cortex of Alzheimer's disease transgenic mice, Neurochem Res 34(1) (2009), 102-108.
32. J. Zhou et al., Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease, J Neurochem 106(5) (2008), 2080-2092.
33. E.M. Blalock et al., Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses, Proc Natl Acad Sci U S A 101(7) (2004), 2173-2178.
34. D.M. Bonifati and U. Kishore, Role of complement in neurodegeneration and neuroinflammation, Mol Immunol 44(5) (2007), 999-1010.
35. P.A. Desplats et al., Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease, J Neurochem 96(3) (2006), 743-757.
36. A. Hodges et al., Regional and cellular gene expression changes in human Huntington's disease brain, Hum Mol Genet 15(6) (2006), 965-977.
37. R. Inagaki et al., Omi / HtrA2 is relevant to the selective vulnerability of striatal neurons in Huntington's disease, Eur J Neurosci 28(1) (2008), 30-40.
38. N.J. Maragakis and J.D. Rothstein, Mechanisms of Disease: astrocytes in neurodegenerative disease, Nat Clin Pract Neurol 2(12) (2006), 679-689.
39. S. Sarkar and D.C. Rubinsztein, Small molecule enhancers of autophagy for neurodegenerative diseases, Mol Biosyst 4(9) (2008), 895-901.
40. H. Wang et al., Nortriptyline delays disease onset in models of chronic neurodegeneration, Eur J Neurosci 26(3) (2007), 633-641.
41. E. Bossy-Wetzel, A. Petrilli and A.B. Knott, Mutant huntingtin and mitochondrial dysfunction, Trends Neurosci 31(12) (2008), 609-616.
42. K. Bossers et al., Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death, Brain Pathol 19(1) (2009), 91-107.
43. S. Mandel, E. Grunblatt and M. Youdim, cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease, J Neural Transm Suppl (60) (2000), 117-124.
44. J.A. Olzmann et al., Selective enrichment of DJ-1 protein in primate striatal neuronal processes: implications for Parkinson's disease, J Comp Neurol 500(3) (2007), 585-599.
45. F. Simunovic et al., Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology, Brain 132(Pt 7) (2009), 1795-1809.
46. P. Teismann and J.B. Schulz, Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation, Cell Tissue Res 318(1) (2004), 149-161.
47. M.A. Hauser et al., Expression profiling of substantia nigra in Parkinson disease progressive supranuclear palsy, and frontotemporal dementia with parkinsonism, Arch Neurol 62(6) (2005), 917-921.
48. A. Bhathena and B.B. Spear, Pharmacogenetics: improving drug and dose selection, Curr Opin Pharmacol 8(5) (2008), 639-646.
49. A.D. Roses et al., Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease), Pharmacogenomics J 7(1) (2007), 10-28.
50. H.S. Hain, J.K. Belknap and J.S. Mogil, Pharmacogenetic evidence for the involvement of 5-hydroxytryptamine (Serotonin)-1B receptors in the mediation of morphine antinociceptive sensitivity, J Pharmacol Exp Ther 291(2) (1999), 444-449.
51. S.D. Mague et al., Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior, Proc Natl Acad Sci U S A 106(26) (2009), 10847-10852.
52. A.H. Harrill et al., Population-based discovery of toxicogenomics biomarkers for hepatotoxicity using a laboratory strain diversity panel, Toxicol Sci 110(1) (2009), 235-243.
53. M. Dillhoff, S.E. Wojcik and M. Bloomston, MicroRNAs in solid tumors, J Surg Res 154(2) (2009), 349-354.
54. Y.S. Lee and A. Dutta, MicroRNAs in cancer, Annu Rev Pathol 4 (2009), 199-227.
55. R. Saba et al., A miRNA signature of prion induced neurodegeneration, PLoS One 3(11) (2008), e3652.
56. K. Wang et al., Circulating microRNAs, potential biomarkers for drug-induced liver injury, Proc Natl Acad SciUSA106(11) (2009), 4402-4407.
57. N.L. Anderson and N.G. Anderson, The human plasma proteome: history, character, and diagnostic prospects, Mol Cell Proteomics 1(11) (2002), 845-867.
58. K. Fujii et al., Multidimensional protein profiling technology and its application to human plasma proteome, J Proteome Res 3(4) (2004), 712-718.
59. J.T. Lathrop et al., Therapeutic potential of the plasma proteome, Curr Opin Mol Ther 5(3) (2003), 250-257.
60. H.J. Lee et al., Biomarker discovery from the plasma proteome using multidimensional fractionation proteomics, Curr Opin Chem Biol 10(1) (2006), 42-49.